Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine

Clinical and Vaccine Immunology

Volumn 21, Issue 3, 2014, Pages 302-311

  Leroux Roels, Geert ^a   Bourguignon, Patricia ^b   Willekens, Julie ^a   Janssens, Michel ^b   Clement, Frédéric ^a   Didierlaurent, Arnaud M ^b   Fissette, Laurence ^b   Roman, François ^b   Boutriau, Dominique ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GSK   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AS01B VACCINE; CHLOROQUINE; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PARALLEL DESIGN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AIDS VACCINES; ANTIMALARIALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHLOROQUINE; CYTOKINES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNIZATION, SECONDARY; MALE; YOUNG ADULT;

EID: 84896768003     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00617-13     Document Type: Article

References (36)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2013. Global fact sheet. UNAIDS, Geneva, Switzerland. http://www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/2012/201207-FactSheet-Global-en.pdf.
2. +T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems. Vaccine 28:7016-7024. http://dx.doi.org/10.1016/j.vaccine.2010.08.035.
3. Berkley SF, Koff WC. 2007. Scientific and policy challenges to development of an AIDS vaccine. Lancet 370:94-101. http://dx.doi.org/10.1016/ S0140-6736(07)61054-X. (Pubitemid 47017469)
4. Carcelain G, Autran B. 2013. Immune interventions in HIV infection. Immunol. Rev. 254:355-371. http://dx.doi.org/10.1111/imr.12083.
5. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789. http://dx.doi.org/10.1182/blood-2005-12-4818. (Pubitemid 43882629)
6. + T cells be of help? Hum. Vaccin. Immunother. 8:1795-1798. http://dx.doi.org/10. 4161/hv.21760.
7. + T cell responses in HIV vaccine development. Nat. Med. 19:143-149. http://dx.doi.org/10.1038/nm.3054.
8. Bourgeois C, Veiga-Fernandes H, Joret AM, Rocha B, Tanchot C. 2002. CD8 lethargy in the absence of CD4 help. Eur. J. Immunol. 32:2199-2207. http://dx.doi.org/10.1002/1521-4141(200208)32:8〈2199::AID-IMMU2199〉3. 0.CO;2-L.
9. + T lymphocytes. Nature 421:852-856. http://dx.doi.org/10.1038/nature01441.
10. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530-1533. http://dx.doi.org/10. 1126/science.1124226.
11. + T cells. J. Exp. Med. 200:701-712. http://dx.doi.org/10.1084/jem. 20041270.
12. Shedlock DJ, Shen H. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337-339. http://dx.doi.org/10.1126/ science.1082305. (Pubitemid 36433726)
13. Sun JC, Bevan MJ. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339-342. http://dx.doi.org/10. 1126/science.1083317. (Pubitemid 36433727)
14. + T cells after acute infection. Nat. Immunol. 5:927-933. http://dx.doi.org/10.1038/ni1105.
15. + T-cell response elicited by recombinant adenovirus vaccines. Mol. Ther. 15:997-1006. http://dx.doi.org/10.1038/sj.mt.6300130.
16. + T cell responses in seronegative volunteers. Clin. Infect. Dis. 52:522-531. http://dx.doi.org/10.1093/cid/ciq160.
17. Harrer T, Plettenberg A, Arastéh K, Van Luzen J, Fätkenheuer G, Jaeger H, Janssens M, Burny W, Collard A, Roman F, Loeliger A, Koutsoukos M, Bourguignon P, Lavreys L, Voss G. 19 October 2013. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study. Vaccine http://dx.doi.org/10. 1016/j.vaccine.2013.10.030.
18. Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepapeliere P, McElrath MJ, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Baden LR, Harro C, Evans T, NIAID HIV Vaccine Trials Network. 2007. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multiprotein recombinant vaccine in uninfected human volunteers. Vaccine 25:510-518. http://dx.doi.org/10.1016/j.vaccine.2006.07.050. (Pubitemid 44856093)
19. + T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals. J. Acquir. Immune. Defic. Syndr. 59:1-9. http://dx.doi.org/10.1097/QAI.0b013e3182373b77.
20. Garulli B, Di Mario G, Sciaraffia E, Accapezzato D, Barnaba V, Castrucci MR. 2013. Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo. Vaccine 31:1717-1724. http://dx.doi.org/10.1016/j.vaccine.2013.01.037.
21. + T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo. Clin. Vaccine Immunol. 15:1497-1504. http://dx.doi.org/10. 1128/CVI.00166-08.
22. + T cell responses against soluble antigens in vivo. J. Exp. Med. 202:817-828. http://dx.doi.org/10.1084/jem.20051106.
23. Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, Yamamoto M, Takeuchi O, Itagaki S, Kumar N, Horii T, Akira S. 2005. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J. Exp. Med. 201: 19 -25. http://dx.doi.org/10.1084/jem.20041836.
24. Hong Z, Jiang Z, Liangxi W, Guofu D, Ping L, Yongling L, Wendong P, Minghai W. 2004. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int. Immunopharmacol. 4:223-234. http://dx.doi.org/10.1016/j.intimp.2003.12.006. (Pubitemid 38296351)
25. Zhou H, Ding G, Liu W, Wang L, Lu Y, Cao H, Zheng J. 2004. Lipopolysaccharide could be internalized into human peripheral blood mononuclear cells and elicit TNF-alpha release, but not via the pathway of Toll-like receptor 4 on the cell surface. Cell Mol. Immunol. 1:373-377.
26. Van Braeckel E, Koutsoukos M, Bourguignon P, Clement F, McNally L, Leroux-Roels G. 2011. Vaccine-induced HIV seropositivity: a problem on the rise. J. Clin. Virol. 50:334-337. http://dx.doi.org/10.1016/j.jcv.2011.01.003.
27. Quah BJ, Warren HS, Parish CR. 2007. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protoc. 2:2049-2056. http://dx.doi.org/10. 1038/nprot.2007.296. (Pubitemid 351565842)
28. Garcon N, Van Mechelen M. 2011. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev. Vaccines 10:471-486. http://dx.doi.org/10.1586/erv.11.29.
29. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garcon N. 2009. AS04, an aluminum saltand TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183:6186-6197. http://dx.doi.org/10.4049/ jimmunol.0901474.
30. Anthony DD, Milkovich KA, Zhang W, Rodriguez B, Yonkers NL, Tary-Lehmann M, Lehman PV. 2012. Dissecting the T cell response: proliferation assays vs. cytokine signatures by ELISPOT. Cells 1:127-140. http://dx.doi.org/10.3390/ cells1020127.
31. Heath SL, Sabbaj S, Bansal A, Kilby JM, Goepfert PA. 2011. CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection. J. Acquir. Immune. Defic. Syndr. 56:213-221. http://dx.doi.org/10.1097/QAI. 0b013e3181ff2aba.
32. Didierlaurent A, Ramirez JC, Gherardi M, Zimmerli SC, Graf M, Orbea HA, Pantaleo G, Wagner R, Esteban M, Kraehenbuhl JP, Sirard JC. 2004. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22:3395-3403. http://dx.doi.org/10.1016/j. vaccine.2004.02.025. (Pubitemid 39078757)
33. Levitz SM, Golenbock DT. 2012. Beyond empiricism: informing vaccine development through innate immunity research. Cell 148:1284-1292. http://dx.doi.org/10.1016/j.cell.2012.02.012.
34. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, Robinson HL, Lennox J, Amara RR. 2007. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells co-expressing three cytokines. J. Virol. 81:12071-12076. http://dx.doi.org/10.1128/JVI.01261-07. (Pubitemid 47623838)
35. + T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81:13904-13915. http://dx.doi.org/10. 1128/JVI.01401-07.
36. + T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. Vaccine 31:3739-3746. http://dx.doi.org/10.1016/j.vaccine.2013.05.021.